61,809,543 shares is a lot of NVDL shares to be owning now
From February 2012 SEC filing :
"The 61,809,543 shares of Common Stock beneficially owned by the Reporting Persons represent 38.1% of the issued and outstanding shares of Common Stock based on 134,890,615 shares of Common Stock outstanding as of October 25, 2011 as set forth by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on November 1, 2011. Of such 61,809,543 shares, 29,995,693, or 19.5%, are beneficially owned by Investments II; 193,233, or .1%, are beneficially owned by Advisors Fund; 30,188,926, or 19.6%, are beneficially owned by Associates II; 31,620,617, or 22.1beneficially owned by each of Investments III and Associates III; and 61,809,543, or 38.1%, are beneficially owned by each of Moorin and Schreiber."
For any newbies here ignore the lowlife #$%$ here who are make idiotic insane claims about who posts messages here rather than what the messages actually are. They are paid to bash this stock so they are obsessed with anybody who does not bash this stock.
Those are SEC Filings and important information that I posted about this stock.
The lowlife basher here with many multiple ID's has NOTHING to post about the SEC Filing but instead he wants to post about who is posting the informtion as if that really means anything.
Ignore the total nutjob who posted so many times about 10 cents.
22 February 2012 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 NOVADEL PHARMA INC. File No. 1-32177 -- CF# 27475 _____________________ NOVADEL PHARMA INC. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 1, 2011. Based on representations by NOVADEL PHARMA INC. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified: Exhibit 10.2 through August 17, 2016 For the Commission, by the Division of Corporation Finance, pursuant to delegated authority: Timothy S. Levenberg Special Counsel From an earlier different SEC Filing: Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”) is entered into as of August 18, 2011 (the “Effective Date”) by and between NOVADEL PHARMA, INC. (“NovaDel”), having an address at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807, and RECHON LIFE SCIENCE AB, (“Rechon”), having an address at Soldattorpsvägen 5, PO Box 60043, 216 10 Limhamn, Sweden. RECITALS WHEREAS, NovaDel develops pharmaceutical products with a focus on developing oral spray formulations of a broad range of marketed treatments for serious diseases, and NovaDel has developed expertise and acquired proprietary rights related to Licensed Product (as defined below); WHEREAS, Rechon has expertise in licensing, developing, manufacturing, marketing and distributing certain pharmaceutical products, and wishes to develop, manufacture and market the Licensed Product as further described herein; and WHEREAS, NovaDel desires to grant a license to Rechon, and Rechon desires to accept a license, with regard to Licensed Product in the Territory on the terms and conditions set forth herein.